The therapeutic potential of PDE4 inhibitors
Authors:
- 1 September 1999
- journal article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 8 (9) , 1301-1325
Abstract
Phosphodiesterase enzymes are responsible for the inactivation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Phosphodiesterase 4 (PDE4) is a cAMP specific phosphodiesterase expressed in inflammatory cells such as eosinophils. Inhibition of PDE4 results in an elevation of cAMP in these cells, which in turn downregulates the inflammatory response. The anti-inflammatory effects of PDE4 inhibitors have been well documented both in vitro and in vivo in a variety of animal models. The potential use of PDE4 inhibitors as anti-inflammatory agents for the treatment of asthma and other inflammatory disorders has received considerable attention from the pharmaceutical industry, but to date, there are no selective PDE4 inhibitors on the market. Early PDE4 inhibitors, typified by rolipram, suffered from dose-limiting side effects, including nausea and emesis, which severely restricted their therapeutic utility. Second generation compounds, including CDP840 and SB207499 (Ariflo™), have been identified with reduced side effect liability. Recent evidence suggests a correlation between side effects and the ability of compounds to bind at the so-called high affinity rolipram binding site (HPDE), whilst beneficial effects appear to correlate with binding at the catalytic site. A number of companies are actively pursuing compounds which exhibit improved affinity for the catalytic site and reduced affinity for the HPDE, in the expectation that this will provide compounds with an improved therapeutic index.Keywords
This publication has 153 references indexed in Scilit:
- 7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as Novel Inhibitors of Human Eosinophil PhosphodiesteraseJournal of Medicinal Chemistry, 1998
- Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific PhosphodiesteraseBiochemical and Biophysical Research Communications, 1998
- Clinical Management of Asthma in the 1990sDrugs, 1996
- Leukotrienes as therapeutic target in asthmaAllergy, 1995
- Rheumatoid ArthritisNew England Journal of Medicine, 1990
- Mechanism for the emetic side effect of xanthine bronchodilatorsLife Sciences, 1990
- Direct in vivo evidence for mast cell degranulation during allergen-induced reactions in manJournal of Allergy and Clinical Immunology, 1986
- Relationships between adenosine, cyclic nucleotides, and xanthines in asthmaJournal of Allergy and Clinical Immunology, 1986
- Inflammatory Mediators in Late Antigen-Induced RhinitisNew England Journal of Medicine, 1985
- A controlled trial of azathioprine in Crohn's diseaseDigestive Diseases and Sciences, 1975